Lyell Immunopharma
The role provides CMC regulatory expertise throughout the product lifecycle for a clinical-stage cell therapy company, interacting with the FDA and leading CMC regulatory risk assessments, documentation, and submission planning. The incumbent collaborates with cross‑functional teams to develop regulatory content for INDs, CTAs, BLAs/MAAs, and other regulatory submissions, while maintaining knowledge of global regulations and best practices.
Headquarters
South San Francisco, California, United States
Company Size
201-500 employees
Founded
2018
Lyell is a fully integrated biopharmaceutical company developing next‑generation T‑cell reprogramming technologies to create durable CAR T‑cell therapies for hematologic malignancies and solid tumors. Their platform-driven approach spans discovery through clinical development, with active programs and trials such as the PiNACLE study for aggressive B‑cell non‑Hodgkin lymphoma and the recently acquired GCC‑targeted candidate LYL273. Lyell is patient‑focused, aiming to improve outcomes for cancers with significant unmet medical need.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Lyell Immunopharma.
35% above the average for this role
HC Wainwright & Co. Maintains Lyell Immunopharma (LYEL) Neutral Recommendation
5 days ago
Manager, Regulatory CMC
Legend Biotech
Director, Regulatory Affairs - CMC/Biologics
ICON plc
Director, CMC Regulatory Affairs
Capricor Therapeutics
Regulatory Director/Sr. Director Regulatory CMC
Beam Therapeutics
Senior Manager, Regulatory Affairs CMC
shionogi
Senior Regulatory Affairs Specialist - CMC
Jobgether